You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies

Authors

  • Tuba N Gide Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Ella McCutcheon Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Nigel Maher Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia NSW Health Pathology, Sydney, NSW, Australia Royal Prince Alfred Hospital, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Yizhe Mao Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Ping Shang Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Alexander M Menzies Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Royal North Shore Hospital, Sydney, NSW, Australia Mater Hospital, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Ines Pires da Silva Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Westmead and Blacktown Hospitals, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • James S Wilmott Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Richard A Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia NSW Health Pathology, Sydney, NSW, Australia Royal Prince Alfred Hospital, Sydney, NSW, Australia PubMed articlesGoogle scholar articles
  • Georgina V Long Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Royal North Shore Hospital, Sydney, NSW, Australia Mater Hospital, Sydney, NSW, Australia PubMed articlesGoogle scholar articles

Citation

Gide TN, McCutcheon E, Maher N, et al
82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0082
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.